Published in Cancer on December 01, 2008
Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol (2014) 1.53
Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. J Am Coll Surg (2015) 1.50
Adrenocortical carcinoma. Endocr Rev (2013) 1.46
Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int (2010) 1.44
Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surg (2016) 1.42
Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg (2010) 1.36
Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol (2012) 1.23
Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2013) 1.20
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol (2013) 1.16
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 1.06
Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol (2011) 1.05
Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol (2011) 1.01
Therapy of adrenocortical cancer: present and future. Am J Cancer Res (2010) 0.96
PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery (2013) 0.95
Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World J Surg (2012) 0.94
Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol (2015) 0.93
Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg (2011) 0.93
Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol (2011) 0.92
Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol (2011) 0.92
KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS One (2011) 0.91
A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2012) 0.91
Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS One (2013) 0.91
Adrenocortical oncocytic carcinoma with recurrent metastases: a case report and review of the literature. World J Surg Oncol (2008) 0.90
CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. PLoS One (2014) 0.89
TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer (2013) 0.89
Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence? PLoS One (2013) 0.88
10 rare tumors that warrant a genetics referral. Fam Cancer (2013) 0.84
Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg (2010) 0.84
Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Ann Surg Oncol (2015) 0.84
Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma. Cancer (2012) 0.84
Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. J Transl Med (2012) 0.83
Survival and prognostic factors for adrenocortical carcinoma: a single institution experience. BMC Urol (2015) 0.82
Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. World J Surg (2012) 0.82
Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer. PLoS One (2016) 0.81
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer (2015) 0.81
Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells. Arch Surg (2010) 0.81
Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Ann Surg Oncol (2015) 0.80
Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study. World J Surg (2016) 0.80
Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. J Surg Oncol (2015) 0.80
Extracellular activation of Wnt signaling through epigenetic dysregulation of Wnt inhibitory factor-1 (Wif-1) is associated with pathogenesis of adrenocortical tumor. Oncotarget (2014) 0.79
Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma. Cancer Med (2015) 0.78
Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature. World J Surg Oncol (2015) 0.78
Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-Term Survival. World J Surg (2016) 0.77
Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability. Ann Surg (2017) 0.77
Gene expression and regulation in adrenocortical tumorigenesis. Biology (Basel) (2012) 0.77
Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava--a European Society of Endocrine Surgeons (ESES) survey. Langenbecks Arch Surg (2011) 0.77
Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment. Drug Des Devel Ther (2016) 0.76
Laparoscopic Adrenalectomy for Large Adrenocortical Carcinoma. JSLS (2015) 0.76
Feminizing Adrenocortical Carcinoma with Distant Metastases: Can Surgery be Considered? Clin Pract (2014) 0.76
Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clin Transl Med (2016) 0.76
Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. J Gastrointest Surg (2016) 0.75
Adrenocortical carcinoma: modern management and evolving treatment strategies. Int J Endocr Oncol (2016) 0.75
Atypical dissemination of lung cancer to the adrenal gland and to the spleen. Contemp Oncol (Pozn) (2012) 0.75
Genetics of Adrenocortical Development and Tumors. Endocrinol Metab Clin North Am (2017) 0.75
Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit? Ann Surg Oncol (2016) 0.75
CpG island methylator phenotype in adrenocortical carcinoma: fact or fiction? J Clin Endocrinol Metab (2013) 0.75
Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg (2015) 0.75
Adrenal incidentalomas in cancer patients are not always "innocent": a case report and review of the literature. Case Rep Med (2013) 0.75
Actual 10-year survivors following resection of adrenocortical carcinoma. J Surg Oncol (2016) 0.75
Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma. Oncotarget (2017) 0.75
Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. J Am Coll Surg (2016) 0.75
Brain metastasis in patients with adrenocortical carcinoma: a clinical series. J Clin Endocrinol Metab (2014) 0.75
Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. J Clin Endocrinol Metab (2016) 0.75
Androgen secreting giant adrenocortical carcinoma with no metastases: A case report and review of the literature. Can Urol Assoc J (2015) 0.75
Predictors of malignancy in primary aldosteronism. Langenbecks Arch Surg (2013) 0.75
Adrenocortical carcinoma surgery-surgical extent and approach. Langenbecks Arch Surg (2016) 0.75
Clinical Case of Metastatic Adrenocortical Carcinoma With Unusual Evolution: Review the Literature. World J Oncol (2015) 0.75
A Case of Hemorrhagic Adrenal Pseudocyst Mimicking Solid Tumor. Am J Case Rep (2017) 0.75
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
Extent of surgery affects survival for papillary thyroid cancer. Ann Surg (2007) 4.73
National failure to operate on early stage pancreatic cancer. Ann Surg (2007) 3.65
Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg (2009) 3.07
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Ann Surg (2011) 2.87
Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer (2007) 2.85
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol (2008) 2.74
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.71
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst (2008) 2.46
Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. JAMA (2013) 2.31
Parathyroid cyst: often mistaken for a thyroid cyst. World J Surg (2007) 2.26
Should small papillary thyroid cancer be observed? A population-based study. Cancer (2014) 2.21
Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg (2014) 2.15
The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract (2009) 2.14
The influence of resident involvement on surgical outcomes. J Am Coll Surg (2011) 2.12
Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch Surg (2008) 2.10
Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol (2012) 2.08
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Adherence with postdischarge venous thromboembolism chemoprophylaxis recommendations after colorectal cancer surgery among elderly Medicare beneficiaries. Ann Surg (2014) 1.97
Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst (2009) 1.92
Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol (2009) 1.90
Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg (2008) 1.90
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol (2009) 1.75
The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg (2009) 1.72
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68
DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab (2012) 1.67
Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy. Ann Surg Oncol (2010) 1.67
Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg (2010) 1.66
Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer (2007) 1.63
Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery (2013) 1.62
Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol (2010) 1.60
Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol (2008) 1.60
Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg (2011) 1.59
Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol (2009) 1.58
Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab (2010) 1.57
Routine prophylactic central neck dissection for low-risk papillary thyroid cancer: a cost-effectiveness analysis. Surgery (2013) 1.56
Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg (2013) 1.56
Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther (2010) 1.55
Risk-based selective referral for cancer surgery: a potential strategy to improve perioperative outcomes. Ann Surg (2010) 1.53
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer (2007) 1.52
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer (2010) 1.51
Variant adrenal venous anatomy in 546 laparoscopic adrenalectomies. JAMA Surg (2013) 1.49
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A (2010) 1.47
Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg (2008) 1.47
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med (2010) 1.46
Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol (2014) 1.46
Variation in lymph node examination after esophagectomy for cancer in the United States. Arch Surg (2012) 1.46
Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg (2008) 1.46
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract (2009) 1.44
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg (2007) 1.44
The role of Surgical Champions in the American College of Surgeons National Surgical Quality Improvement Program--a national survey. J Surg Res (2010) 1.43
The significant role of mast cells in cancer. Cancer Metastasis Rev (2011) 1.42
Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg (2007) 1.41
Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid (2009) 1.41
Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid (2005) 1.40
Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg (2008) 1.39
Pancreatic mucinous cystic neoplasm size using CT volumetry, spherical and ellipsoid formulas: validation study. JOP (2014) 1.38
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res (2010) 1.38
Predictors of airway complications after thyroidectomy for substernal goiter. Arch Surg (2004) 1.37
Thyroid cancer gender disparity. Future Oncol (2010) 1.36
Gastric cancer. J Natl Compr Canc Netw (2010) 1.35
Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem (2011) 1.35
Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer (2011) 1.34
Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid (2010) 1.33
Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2011) 1.31
Effect of surgeon training, specialization, and experience on outcomes for cancer surgery: a systematic review of the literature. Ann Surg Oncol (2009) 1.30
Effect of postdischarge morbidity and mortality on comparisons of hospital surgical quality. Ann Surg (2010) 1.30
Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg (2010) 1.30
Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum (2009) 1.29
Parathyroid cancer. Semin Oncol (2010) 1.28
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer (2008) 1.28
A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery (2009) 1.27
MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer (2011) 1.26
Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma. J Am Coll Surg (2003) 1.25
Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg (2007) 1.25
Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy. Am J Surg (2011) 1.25
From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol (2005) 1.24
The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg (2008) 1.23
Surgeons' perceptions of public reporting of hospital and individual surgeon quality. Med Care (2013) 1.22
Axillary recurrence after sentinel node biopsy. Ann Surg Oncol (2004) 1.20